Cara Therapeutics/Vifor Pharma's Korsuva US Application In Pruritus Accepted For Review

Comments
Loading...
  • The FDA has accepted Cara Therapeutics Inc's (NASDAQ: CARA) and its partner's Vifor Pharma GNHAF marketing application for Korsuva (difelikefalin) solution for injection for pruritus (or itch) in hemodialysis patients.
  • Under priority review status, the target action date is August 23.
  • The agency also stated that currently, it is not planning to hold an advisory committee for the application.
  • If approved, Korsuva injection would be the first therapy for the treatment of pruritus in hemodialysis patients.
  • Price Action: CARA shares are up 8.40% at $18.09 in the premarket trading on the last check Monday.
CARA Logo
CARACara Therapeutics Inc
$5.432.07%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
87.38
Growth
-
Quality
-
Value
27.56
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: